Pharmacological inhibition of IRAP as a novel antifibrotic strategy

IRAP 的药理学抑制作为一种新型抗纤维化策略

• 批准号: nhmrc : 1146049
• 负责人: A/Pr Chrishan Samuel
• 金额: $ 70.07万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2018
• 资助国家: 澳大利亚
• 起止时间: 2018-01-01 至 2021-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/pharmacological-inhibition-irap-antifibrotic-strategy/1320586
• 关键词: Pharmacological; inhibition; IRAP; novel; antifibrotic

There are very few treatments that can reduce heart stiffening, called fibrosis, which is seen in patients with high blood pressure or in patients who have had a heart attack. This project will test new drugs that we have developed that act by a unique mechanism to reverse or prevent cardiovascular disease in patients with poorly-functioning hearts and blood vessels.

很少有治疗方法可以减少心脏硬化，称为纤维化，见于高血压患者或心脏病发作患者。这个项目将测试我们开发的新药，这些新药通过一种独特的机制来逆转或预防心脏和血管功能不佳的患者的心血管疾病。